Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | BLK | P51451 | 1/20 | 0.67 |
| ▸ | BMX | P51813 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 1/20 | 0.67 |
| ▸ | BTK | Q06187 | 1/20 | 0.67 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992732 | 1.00 | EGFR (1.00) | EGFRERBB2SRCFYNBLK | |
| SCHEMBL2991092 | 0.91 | EGFR (0.84) | EGFRERBB2SRCFYNBLK | |
| SCHEMBL4185005 | 0.89 | EGFR (0.79) | EGFRERBB2SRCFYNBLK | |
| SCHEMBL2986366 | 0.87 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL27435925 | 0.83 | EGFR (0.72) | EGFRERBB2SRCFYNBLK | |
| SCHEMBL7242465 | 0.81 | EGFR (0.68) | EGFRERBB2SRCFYNLRRK2 | |
| SCHEMBL7128726 | 0.81 | EGFR (0.68) | EGFRERBB2SRCFYNBLK | |
| SCHEMBL2680536 | 0.80 | EGFR (1.00) | EGFRERBB2SRCFYNBLK | |
| SCHEMBL29359583 | 0.80 | EGFR (1.00) | EGFRERBB2SRCFYNBLK | |
| SCHEMBL7238227 | 0.80 | EGFR (0.68) | EGFRERBB2SRCFYNLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | EGFR 1892/4885ERBB2 2230/4885SRC 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.